Sana Pharma has obtained registration and trading license for its Nitrus® Ointment from the Saudi Food and Drug Corporation, where it was released and made available in pharmacies. Nitrus® Ointment...
إجتماع سنا للأبحاث الصيدلانية السنوي للمساهمين
تدعو شركة سنا للأبحاث الصيدلانية السادة المساهمين لحضور الإجتماع السنوي العادي الذي سوف يعقد عبر تقنية مايكروسوفت تيمز يوم الثلاثاء 17\5\2021 في تمام...
Sancovir (Favipiravir) registration
Sana Pharma has recently obtained the approval of Sancovir (Favipiravir) drug by Jordan Food and Drug Administration. This drug is equivalent to the Japanese...
Sana Pharma is pleased to announce that a clinical study entitled "The impact of pharmaceutical care on the efficacy and safety of transdermal glucosamine sulfate and capsaicin for joint pain" has...
As a part of the corporate social responsibility to save our counrty and beloved people during the pandemic of coronavirus, Sana Pharma has decided to:
• Grant the right to manufacture its sanitizing...
Sana Pharma partners in Romania “Senera Pharma” participated in the “7th national congress of diabetic neuropathy and diabetic foot” that held in Bucharest, Romania through a presentation in...
Sana Pharma has successfully registered its manufacturing site at Iraq ministry of health .
Sana Pharma has been approved by Jordan FDA as third party analytical site for NDMA/NDEA carcinogenic of Valsartan family.
Sana Pharma has the renewal of ISO 13485 certificate (medical devices-quality management system) which allow Sana Pharma to export its products to the European market.
Collaboration between the Faculty of Pharmacy/University of Jordan represented by the University President, Prof. Abdulkarim Al-Qudah, and Sana Pharma represented by the General Manager, Dr. Samer Al...